Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:ARMP NASDAQ:CVAC NASDAQ:SDGR NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARMPArmata Pharmaceuticals$7.58+1.5%$9.64$1.74▼$16.34$274.23M1.2165,402 shs77,945 shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/ASDGRSchrodinger$14.45-1.0%$12.89$10.94▼$23.75$1.08B1.641.29 million shs863,692 shsSVRASavara$5.26-0.2%$5.29$1.98▼$7.01$1.08B0.261.53 million shs1.25 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARMPArmata Pharmaceuticals-1.19%-2.86%-17.00%-29.13%+267.98%CVACCureVac0.00%0.00%0.00%0.00%+14.50%SDGRSchrodinger+3.18%-7.89%+15.05%+16.71%-45.30%SVRASavara+3.54%-0.57%+3.74%+0.38%+139.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARMPArmata Pharmaceuticals$7.58+1.5%$9.64$1.74▼$16.34$274.23M1.2165,402 shs77,945 shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/ASDGRSchrodinger$14.45-1.0%$12.89$10.94▼$23.75$1.08B1.641.29 million shs863,692 shsSVRASavara$5.26-0.2%$5.29$1.98▼$7.01$1.08B0.261.53 million shs1.25 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARMPArmata Pharmaceuticals-1.19%-2.86%-17.00%-29.13%+267.98%CVACCureVac0.00%0.00%0.00%0.00%+14.50%SDGRSchrodinger+3.18%-7.89%+15.05%+16.71%-45.30%SVRASavara+3.54%-0.57%+3.74%+0.38%+139.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARMPArmata Pharmaceuticals 2.67Moderate Buy$15.0097.89% UpsideCVACCureVac 1.67Reduce$5.2512.66% UpsideSDGRSchrodinger 2.33Hold$20.2540.14% UpsideSVRASavara 2.88Moderate Buy$10.1492.83% UpsideCurrent Analyst Ratings BreakdownLatest ARMP, SVRA, CVAC, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026ARMPArmata Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/14/2026SDGRSchrodinger Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $17.004/24/2026SVRASavara OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.00 ➝ $11.004/21/2026SVRASavara Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026SDGRSchrodinger KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$25.00 ➝ $20.003/17/2026SDGRSchrodinger UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$18.00 ➝ $13.003/16/2026SVRASavara William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.003/16/2026SVRASavara HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARMPArmata Pharmaceuticals$4.90M56.79N/AN/A($6.00) per share-1.26CVACCureVac$70.74M14.78$0.99 per share4.73$3.36 per share1.39SDGRSchrodinger$255.87M4.17N/AN/A$4.94 per share2.93SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARMPArmata Pharmaceuticals-$173.80M-$1.64N/AN/AN/A-5,432.79%N/A-75.29%8/11/2026 (Estimated)CVACCureVac$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/ASDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)SVRASavara-$118.84M-$0.56N/AN/AN/AN/A-87.19%-66.42%8/12/2026 (Estimated)Latest ARMP, SVRA, CVAC, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ARMPArmata Pharmaceuticals-$0.38-$3.16-$2.78-$3.16$0.74 million$0.79 million5/12/2026Q1 2026SVRASavara-$0.14-$0.15-$0.01-$0.15$0.50 millionN/A5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million3/25/2026Q4 2025ARMPArmata Pharmaceuticals-$0.19-$3.42-$3.23-$3.42$0.74 million$1.09 million3/13/2026Q4 2025SVRASavara-$0.12-$0.13-$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARMPArmata PharmaceuticalsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARMPArmata PharmaceuticalsN/A0.640.64CVACCureVac0.033.703.69SDGRSchrodingerN/A2.742.74SVRASavara0.1713.4713.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARMPArmata Pharmaceuticals3.57%CVACCureVac17.26%SDGRSchrodinger79.05%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipARMPArmata Pharmaceuticals84.50%CVACCureVac2.15%SDGRSchrodinger10.10%SVRASavara5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARMPArmata Pharmaceuticals7036.71 million5.69 millionNot OptionableCVACCureVac880224.34 million219.52 millionOptionableSDGRSchrodinger79073.82 million66.37 millionOptionableSVRASavara20204.93 million194.07 millionOptionableARMP, SVRA, CVAC, and SDGR HeadlinesRecent News About These CompaniesSavara Announces New Employment Inducement GrantJune 12 at 4:05 PM | businesswire.comSavara Announces Chief Financial and Administrative Officer TransitionJune 8, 2026 | businesswire.comAssessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term ReturnsJune 8, 2026 | finance.yahoo.comOppenheimer Sticks to Their Buy Rating for Savara (SVRA)June 5, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)May 30, 2026 | theglobeandmail.comSavara Announces Participation in the 2026 Jefferies Global Healthcare ConferenceMay 27, 2026 | businesswire.comSavara: The Rare Disease Funnel Is Becoming A Commercial AssetMay 27, 2026 | seekingalpha.comSavara Inc. (SVRA) Reports Q1 Financial ResultsMay 22, 2026 | insidermonkey.com5 Best Penny Stocks to Buy for Long TermMay 21, 2026 | insidermonkey.comSavara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...May 20, 2026 | timesargus.comTSavara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026May 20, 2026 | businesswire.comSavara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar ...May 19, 2026 | uk.finance.yahoo.comSavara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)May 19, 2026 | businesswire.comSavara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)May 18, 2026 | businesswire.comGuggenheim Reaffirms Their Buy Rating on Savara (SVRA)May 15, 2026 | theglobeandmail.comSavara (SVRA) Receives a Buy from Piper SandlerMay 15, 2026 | theglobeandmail.comSavara Reports First Quarter Financial Results and Provides Business UpdateMay 12, 2026 | businesswire.comSavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor ConferenceMay 12, 2026 | cadillacnews.comCAssessing Savara (SVRA) Valuation After FDA Extends Priority Review For MolgramostimApril 26, 2026 | finance.yahoo.comSavara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech SegmentApril 19, 2026 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARMP, SVRA, CVAC, and SDGR Company DescriptionsArmata Pharmaceuticals NYSEAMERICAN:ARMP$7.58 +0.11 (+1.47%) Closing price 04:10 PM EasternExtended Trading$7.50 -0.08 (-1.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.CureVac NASDAQ:CVAC$4.66 0.00 (0.00%) As of 06/11/2026CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Schrodinger NASDAQ:SDGR$14.45 -0.15 (-1.03%) Closing price 04:00 PM EasternExtended Trading$14.36 -0.09 (-0.66%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Savara NASDAQ:SVRA$5.26 -0.01 (-0.19%) Closing price 04:00 PM EasternExtended Trading$5.22 -0.04 (-0.86%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
